Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
LeqvioⓇ - siRNA (regulation of LDL-C)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT04659863 ORION-13 (CKJX839C12302)
Hyperlipidemia, pediatrics
Phase 3
15
Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline
to day 330
Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360,
inclisiran sodium 300mg on Days 450 and 630;Group 2: Placebo on Days 1, 90,
270, inclisiran sodium 300mg on Days 360, 450 and 630.
Adolescents (12 to less than 18 years) with homozygous familial
hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol
(LDL-C)
NCT05030428 VICTORION-2P (CKJX839B12302)
CVRR
Phase 3
15000
1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular
Events)
Arm 1: Experimental Inclisiran sodium, Subcutaneous injection
Arm 2: Placebo Comparator, Placebo Subcutaneous injection
Participants with established cardiovascular disease (CVD)
Read-out Milestone(s)
2025
Publication
TBD
51 Investor Relations | Q1 2022 Results
2027
TBD
1 NOVARTIS | Reimagining MedicineView entire presentation